[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse PTGIS

Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass membrane protein
Domain PF00067 Cytochrome P450
Function

Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).

> Gene Ontology
 
Biological Process GO:0001516 prostaglandin biosynthetic process
GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0001676 long-chain fatty acid metabolic process
GO:0001890 placenta development
GO:0001893 maternal placenta development
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006692 prostanoid metabolic process
GO:0006693 prostaglandin metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006769 nicotinamide metabolic process
GO:0006809 nitric oxide biosynthetic process
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0009820 alkaloid metabolic process
GO:0016053 organic acid biosynthetic process
GO:0019369 arachidonic acid metabolic process
GO:0019371 cyclooxygenase pathway
GO:0030522 intracellular receptor signaling pathway
GO:0031348 negative regulation of defense response
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032102 negative regulation of response to external stimulus
GO:0033559 unsaturated fatty acid metabolic process
GO:0035357 peroxisome proliferator activated receptor signaling pathway
GO:0035358 regulation of peroxisome proliferator activated receptor signaling pathway
GO:0035360 positive regulation of peroxisome proliferator activated receptor signaling pathway
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0044283 small molecule biosynthetic process
GO:0044706 multi-multicellular organism process
GO:0045019 negative regulation of nitric oxide biosynthetic process
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0046209 nitric oxide metabolic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0046457 prostanoid biosynthetic process
GO:0046697 decidualization
GO:0048514 blood vessel morphogenesis
GO:0048608 reproductive structure development
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0060135 maternal process involved in female pregnancy
GO:0061458 reproductive system development
GO:0070482 response to oxygen levels
GO:0070555 response to interleukin-1
GO:0070741 response to interleukin-6
GO:0071347 cellular response to interleukin-1
GO:0071354 cellular response to interleukin-6
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0072330 monocarboxylic acid biosynthetic process
GO:0072524 pyridine-containing compound metabolic process
GO:0072593 reactive oxygen species metabolic process
GO:0097194 execution phase of apoptosis
GO:1900117 regulation of execution phase of apoptosis
GO:1900119 positive regulation of execution phase of apoptosis
GO:1901342 regulation of vasculature development
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903427 negative regulation of reactive oxygen species biosynthetic process
GO:1904018 positive regulation of vasculature development
GO:1904406 negative regulation of nitric oxide metabolic process
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000378 negative regulation of reactive oxygen species metabolic process
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0004497 monooxygenase activity
GO:0005506 iron ion binding
GO:0008116 prostaglandin-I synthase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016853 isomerase activity
GO:0016860 intramolecular oxidoreductase activity
GO:0020037 heme binding
GO:0046906 tetrapyrrole binding
Cellular Component GO:0005901 caveola
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa00590 Arachidonic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-2142753: Arachidonic acid metabolism
R-HSA-194068: Bile acid and bile salt metabolism
R-HSA-211859: Biological oxidations
R-HSA-211897: Cytochrome P450 - arranged by substrate type
R-HSA-211979: Eicosanoids
R-HSA-211976: Endogenous sterols
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-197264: Nicotinamide salvaging
R-HSA-196807: Nicotinate metabolism
R-HSA-211945: Phase 1 - Functionalization of compounds
R-HSA-211994: Sterols are 12-hydroxylated by CYP8B1
R-HSA-2162123: Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
R-HSA-192105: Synthesis of bile acids and bile salts
R-HSA-193775: Synthesis of bile acids and bile salts via 24-hydroxycholesterol
R-HSA-193807: Synthesis of bile acids and bile salts via 27-hydroxycholesterol
R-HSA-193368: Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTGIS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTGIS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTGIS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.830.157
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.5850.185
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2670.764
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2980.736
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1490.945
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8610.75
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0670.913
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0290.984
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0650.966
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2040.867
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1480.462
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6910.0234
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTGIS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTGIS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTGIS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTGIS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTGIS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTGIS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTGIS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTGIS
Nameprostaglandin I2 (prostacyclin) synthase
Aliases PGIS; CYP8A1; cytochrome P450, family 8, subfamily A, polypeptide 1; CYP8; PTGI; prostaglandin I2 synthase; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTGIS collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PTGIS.
ID Name Drug Type Targets #Targets
DB00812PhenylbutazoneSmall MoleculePTGIS, PTGS1, PTGS23
DB01240EpoprostenolSmall MoleculeP2RY12, PTGIR, PTGIS3
DB08675(5Z)-7-{(1R,4S,5R,6R)-6-[(1E)-1-Octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acidSmall MoleculePTGIS1